Cite
HARVARD Citation
Elmaagacli, A. et al. (2020). Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide. Leukemia & lymphoma. 61 (2), pp. 485-487. [Online].